{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T04:26:15Z","timestamp":1787199975960,"version":"build-2736575974"},"reference-count":42,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T00:00:00Z","timestamp":1787184000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>This study aimed to evaluate and compare the efficacy and safety of methoxy polyethylene glycol-epoetin beta, a continuous erythropoietin receptor activator (CERA), and roxadustat in the management of renal anemia among patients undergoing maintenance hemodialysis (MHD).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A retrospective analysis was conducted involving 60 patients with renal anemia receiving MHD at a single center between December 2024 and June 2025. Participants were assigned to one of two treatment groups (n = 30 per group). The CERA group received intravenous methoxy polyethylene glycol-epoetin beta at a starting dose of 100\u00a0\u03bcg, administered every 2\u20136\u00a0weeks with dose adjustments based on hemoglobin (Hb) levels. The roxadustat group received oral roxadustat capsules, initiated at 100\u00a0mg three times weekly, with dose modifications ranging from 20 to 150\u00a0mg according to Hb responses. After 6\u00a0months of treatment, the primary outcome was the between-group difference in Hb change from baseline to month 6. Secondary outcomes included Hb target attainment, defined strictly as 110\u2013130\u00a0g\/L, and hypertension rate. Missing baseline covariates were imputed using k-nearest neighbors (k = 10) before overlap weighting. The overlap-weighting model included baseline Hb, age, sex, primary kidney disease, hypertension at baseline, baseline parathyroid hormone, body weight, baseline C-reactive protein, dialysis vintage, prior ESA type\/dose, baseline ferritin, and baseline transferrin. The weighted Hb outcome model was a mixed model for repeated measures including treatment group, time, treatment-by-time interaction, and baseline Hb. Weighted generalized estimating equation models were used for binary repeated outcomes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>After overlap weighting, baseline Hb was 93.0 (14.49) g\/L in the roxadustat group and 93.0 (15.79) g\/L in the CERA group. At month 6, weighted mean Hb was 103.4 (14.87) g\/L and 111.7 (10.23) g\/L, respectively. The 6-month difference in least-squares mean Hb change for CERA versus roxadustat was 8.27 (1.87, 14.67) (P = 0.012). Weighted Hb target attainment at month 6 was 37.9% in the roxadustat group and 50.6% in the CERA group; the month 6 treatment-by-time interaction RR was 1.16 (0.26\u20135.11) (P = 0.846). Weighted hypertension rates at month 6 were 60.7% and 57.5%, respectively; the month 6 treatment-by-time interaction RR was 0.95 (0.57\u20131.57) (P = 0.834).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>In this small retrospective cohort, CERA was associated with a larger 6-month Hb increase than roxadustat after overlap weighting. Hb target attainment and hypertension-rate comparisons did not show statistically significant treatment-by-time interaction effects. Because treatment allocation reflected clinical practice and patient preference, residual selection bias remains an important competing explanation.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fphar.2026.1862251","type":"journal-article","created":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T04:15:53Z","timestamp":1787199353000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Comparative efficacy and safety of methoxy polyethylene glycol-epoetin beta and roxadustat in the management of renal anemia in maintenance hemodialysis"],"prefix":"10.3389","volume":"17","author":[{"given":"Hai-E.","family":"Tang","sequence":"first","affiliation":[{"name":"Department of Nephrology, The Affiliated Guangdong Second Provincial General Hospital of Jinan University","place":["Guangzhou, Guangdong, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan-E.","family":"Qiu","sequence":"additional","affiliation":[{"name":"Department of Nephrology, The Affiliated Guangdong Second Provincial General Hospital of Jinan University","place":["Guangzhou, Guangdong, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rong-Xiu","family":"Ge","sequence":"additional","affiliation":[{"name":"Department of Nephrology, The Affiliated Guangdong Second Provincial General Hospital of Jinan University","place":["Guangzhou, Guangdong, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao-Jie","family":"Lin","sequence":"additional","affiliation":[{"name":"Department of Nephrology, The Affiliated Guangdong Second Provincial General Hospital of Jinan University","place":["Guangzhou, Guangdong, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qin","family":"Zhao","sequence":"additional","affiliation":[{"name":"Department of Nephrology, The Affiliated Guangdong Second Provincial General Hospital of Jinan University","place":["Guangzhou, Guangdong, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiang","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Nephrology, The Affiliated Guangdong Second Provincial General Hospital of Jinan University","place":["Guangzhou, Guangdong, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,8,20]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1111\/1744-9987.13609","article-title":"Factors affecting the doses of roxadustat vs darbepoetin alfa for anemia treatment in hemodialysis patients","volume":"25","author":"Akizawa","year":"2021","journal-title":"Ther. Apher. Dial."},{"key":"B2","doi-asserted-by":"publisher","first-page":"3083","DOI":"10.1002\/sim.3697","article-title":"Balance diagnostics for comparing the distribution of baseline covariates between treatment groups in propensity-score matched samples","volume":"28","author":"Austin","year":"2009","journal-title":"Stat. Med."},{"key":"B3","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1080\/00273171.2011.568786","article-title":"An introduction to propensity score methods for reducing the effects of confounding in observational studies","volume":"46","author":"Austin","year":"2011","journal-title":"Multivar. Behav. Res."},{"key":"B4","doi-asserted-by":"publisher","first-page":"1631","DOI":"10.1681\/ASN.2011111078","article-title":"Mechanisms of anemia in CKD","volume":"23","author":"Babitt","year":"2012","journal-title":"J. Am. Soc. Nephrol."},{"key":"B5","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1016\/j.kint.2025.06.005","article-title":"Executive summary of the KDIGO 2026 clinical practice guideline for the management of anemia in chronic kidney disease (CKD)","volume":"109","author":"Babitt","year":"2026","journal-title":"Kidney Int."},{"key":"B6","doi-asserted-by":"publisher","first-page":"5345","DOI":"10.1007\/s12325-021-01903-7","article-title":"Efficacy and cardiovascular safety of roxadustat in dialysis-dependent chronic kidney disease: pooled analysis of four phase 3 studies","volume":"38","author":"Barratt","year":"2021","journal-title":"Adv. Ther."},{"key":"B7","doi-asserted-by":"publisher","first-page":"1546","DOI":"10.1007\/s12325-023-02433-0","article-title":"Safety of roxadustat Versus erythropoiesis-stimulating agents in patients with anemia of non-dialysis-dependent or incident-to-dialysis chronic kidney disease: pooled analysis of four phase 3 studies","volume":"40","author":"Barratt","year":"2023","journal-title":"Adv. Ther."},{"key":"B8","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1056\/NEJM199808273390903","article-title":"The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin","volume":"339","author":"Besarab","year":"1998","journal-title":"N. Engl. J. Med."},{"key":"B9","doi-asserted-by":"publisher","first-page":"4009","DOI":"10.1093\/ndt\/gfq305","article-title":"Maintenance treatment of renal anaemia in haemodialysis patients with methoxy polyethylene glycol-epoetin beta versus darbepoetin alfa administered monthly: a randomized comparative trial","volume":"25","author":"Carrera","year":"2010","journal-title":"Nephrol. Dial. Transpl."},{"key":"B10","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.1056\/NEJMoa1813599","article-title":"Roxadustat for anemia in patients with kidney disease not receiving dialysis","volume":"381","author":"Chen","year":"","journal-title":"N. Engl. J. Med."},{"key":"B11","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1056\/NEJMoa1901713","article-title":"Roxadustat treatment for anemia in patients undergoing long-term dialysis","volume":"381","author":"Chen","year":"","journal-title":"N. Engl. J. Med."},{"key":"B12","doi-asserted-by":"publisher","first-page":"303","DOI":"10.3390\/jcm14020303","article-title":"Efficacy and safety of roxadustat in patients with CKD: pooled analysis by baseline inflammation status","volume":"14","author":"Choukroun","year":"2025","journal-title":"J. Clin. Med."},{"key":"B13","doi-asserted-by":"publisher","first-page":"748","DOI":"10.3760\/cma.j.cn112138-20220909-00670","article-title":"Management of hypertension in non-dialysis and dialysis patients with chronic kidney disease: chinese expert consensus","volume":"62","year":"2023","journal-title":"Chin. J. Intern. Med."},{"key":"B14","doi-asserted-by":"publisher","first-page":"2071","DOI":"10.1056\/NEJMoa062276","article-title":"Normalization of hemoglobin level in patients with chronic kidney disease and anemia","volume":"355","author":"Dr\u00fceke","year":"2006","journal-title":"N. Engl. J. Med."},{"key":"B15","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1093\/ckj\/sfu079","article-title":"Once-monthly continuous erythropoietin receptor activator (CERA) for haemoglobin maintenance in haemodialysis patients with chronic renal anaemia","volume":"7","author":"Duman","year":"2014","journal-title":"Clin. Kidney J."},{"key":"B16","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1053\/j.ajkd.2017.09.026","article-title":"Update on anemia in ESRD and earlier stages of CKD: core curriculum 2018","volume":"71","author":"Fishbane","year":"2018","journal-title":"Am. J. Kidney Dis."},{"key":"B17","doi-asserted-by":"publisher","first-page":"850","DOI":"10.1681\/ASN.2020111638","article-title":"Roxadustat Versus epoetin alfa for treating anemia in patients with chronic kidney disease on dialysis: results from the randomized phase 3 ROCKIES study","volume":"33","author":"Fishbane","year":"2022","journal-title":"J. Am. Soc. Nephrol."},{"key":"B18","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1016\/j.ijcard.2022.12.051","article-title":"Not baseline but time-dependent erythropoiesis-stimulating agent responsiveness predicts cardiovascular disease in hemodialysis patients receiving epoetin beta pegol: a multicenter prospective PARAMOUNT-HD study","volume":"375","author":"Fujii","year":"2023","journal-title":"Int. J. Cardiol."},{"key":"B19","doi-asserted-by":"publisher","first-page":"4217","DOI":"10.3390\/jcm12134217","article-title":"Iron parameters in patients treated with roxadustat for anemia of chronic kidney disease","volume":"12","author":"Ganz","year":"2023","journal-title":"J. Clin. Med."},{"key":"B20","doi-asserted-by":"publisher","first-page":"12","DOI":"10.2174\/1570161118666200317151000","article-title":"Antihypertensive therapy in patients receiving maintenance hemodialysis: a narrative review of the available clinical-trial evidence","volume":"19","author":"Georgianos","year":"2021","journal-title":"Curr. Vasc. Pharmacol."},{"key":"B21","doi-asserted-by":"publisher","first-page":"1553","DOI":"10.1007\/s12325-023-02728-2","article-title":"Risk factors for thromboembolic events in patients with dialysis-dependent CKD: pooled analysis of four global roxadustat phase 3 trials","volume":"41","author":"Hamano","year":"2024","journal-title":"Adv. Ther."},{"key":"B22","first-page":"737","article-title":"Variables affecting darbepoetin resistance index in hemodialysis patients","volume":"28","author":"Hejaili","year":"2017","journal-title":"Saudi J. Kidney Dis. Transpl."},{"key":"B23","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1016\/j.kint.2025.06.006","article-title":"KDIGO 2026 clinical practice guideline for the management of anemia in chronic kidney disease (CKD)","volume":"109","author":"Berns","year":"2026","journal-title":"Kidney Int."},{"key":"B24","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1159\/000438870","article-title":"Minor elevation in C-Reactive protein levels predicts incidence of erythropoiesis-stimulating agent hyporesponsiveness among hemodialysis patients","volume":"131","author":"Kimachi","year":"2015","journal-title":"Nephron"},{"key":"B25","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1053\/j.ajkd.2007.08.013","article-title":"Efficacy of intravenous methoxy polyethylene glycol-epoetin beta administered every 2 weeks compared with epoetin administered 3 times weekly in patients treated by hemodialysis or peritoneal dialysis: a randomized trial","volume":"50","author":"Klinger","year":"2007","journal-title":"Am. J. Kidney Dis."},{"key":"B26","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1016\/j.kint.2023.05.009","article-title":"Novel anemia therapies in chronic kidney disease: conclusions from a kidney disease: improving global outcomes (KDIGO) controversies conference","volume":"104","author":"Ku","year":"2023","journal-title":"Kidney Int."},{"key":"B27","doi-asserted-by":"publisher","first-page":"1415","DOI":"10.1016\/S0140-6736(07)61599-2","article-title":"Intravenous methoxy polyethylene glycol-epoetin beta for haemoglobin control in patients with chronic kidney disease who are on dialysis: a randomised non-inferiority trial (MAXIMA)","volume":"370","author":"Levin","year":"2007","journal-title":"Lancet"},{"key":"B28","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1093\/aje\/kwy201","article-title":"Addressing extreme propensity scores via the overlap weights","volume":"188","author":"Li","year":"2019","journal-title":"Am. J. Epidemiol."},{"key":"B29","doi-asserted-by":"publisher","first-page":"1701","DOI":"10.2215\/CJN.01380219","article-title":"Cardiovascular safety and all-cause mortality of methoxy polyethylene glycol-epoetin beta and other erythropoiesis-stimulating agents in anemia of CKD: a randomized noninferiority trial","volume":"14","author":"Locatelli","year":"2019","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"B30","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1056\/NEJMoa1810742","article-title":"Intravenous iron in patients undergoing maintenance hemodialysis","volume":"380","author":"Macdougall","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"B31","doi-asserted-by":"publisher","first-page":"2019","DOI":"10.1056\/NEJMoa0907845","article-title":"A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease","volume":"361","author":"Pfeffer","year":"2009","journal-title":"N. Engl. J. Med."},{"key":"B32","doi-asserted-by":"publisher","first-page":"1717","DOI":"10.1093\/ndt\/gfab051","article-title":"Roxadustat for anemia in patients with end-stage renal disease incident to dialysis","volume":"36","author":"Provenzano","year":"","journal-title":"Nephrol. Dial. Transpl."},{"key":"B33","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1016\/j.ekir.2020.12.018","article-title":"Pooled analysis of roxadustat for anemia in patients with kidney failure incident to dialysis","volume":"6","author":"Provenzano","year":"","journal-title":"Kidney Int. Rep."},{"key":"B34","doi-asserted-by":"publisher","first-page":"1190","DOI":"10.2215\/CJN.16191020","article-title":"Efficacy and cardiovascular safety of roxadustat for treatment of anemia in patients with non-dialysis-dependent CKD: pooled results of three randomized clinical trials","volume":"16","author":"Provenzano","year":"","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"B35","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1053\/j.ackd.2019.04.004","article-title":"Hypoxia-inducible factor activators in renal anemia: current clinical experience","volume":"26","author":"Sanghani","year":"2019","journal-title":"Adv. Chronic Kidney Dis."},{"key":"B36","doi-asserted-by":"publisher","first-page":"2085","DOI":"10.1056\/NEJMoa065485","article-title":"Correction of anemia with epoetin alfa in chronic kidney disease","volume":"355","author":"Singh","year":"2006","journal-title":"N. Engl. J. Med."},{"key":"B37","doi-asserted-by":"publisher","first-page":"e84943","DOI":"10.1371\/journal.pone.0084943","article-title":"Prevalence of anemia in chronic kidney disease in the United States","volume":"9","author":"Stauffer","year":"2014","journal-title":"PLoS One"},{"key":"B38","doi-asserted-by":"publisher","first-page":"2417","DOI":"10.1001\/jama.2020.7819","article-title":"Overlap weighting: a propensity score method that mimics attributes of a randomized clinical trial","volume":"323","author":"Thomas","year":"2020","journal-title":"JAMA"},{"key":"B39","doi-asserted-by":"publisher","first-page":"e296","DOI":"10.1371\/journal.pmed.0040296","article-title":"The strengthening the reporting of observational studies in epidemiology (STROBE) statement: guidelines for reporting observational studies","volume":"4","author":"von Elm","year":"2007","journal-title":"PLoS Med."},{"key":"B40","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1056\/NEJMra041809","article-title":"Anemia of chronic disease","volume":"352","author":"Weiss","year":"2005","journal-title":"N. Engl. J. Med."},{"key":"B41","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1186\/S41100-017-0114-Y","article-title":"Japanese society for dialysis therapy: guidelines for renal anemia in chronic kidney disease","volume":"3","author":"Yamamoto","year":"2015","journal-title":"Ren. Replace. Ther."},{"key":"B42","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1093\/aje\/kwh090","article-title":"A modified poisson regression approach to prospective studies with binary data","volume":"159","author":"Zou","year":"2004","journal-title":"Am. J. Epidemiol."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2026.1862251\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T04:15:56Z","timestamp":1787199356000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2026.1862251\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,20]]},"references-count":42,"alternative-id":["10.3389\/fphar.2026.1862251"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2026.1862251","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,20]]},"article-number":"1862251"}}